Tag Archives: coronary disease

Los stent autoxpandibles son superiores a los de balón expandibles en el territorio ilíaco

Self-Expanding Stents Are Superior to Balloon-Expandable Stents in the Iliac Arteries

Self-Expanding Stents Are Superior to Balloon-Expandable Stents in the Iliac Arteries

Courtesy of Dr. Carlos Fava. Severe atherosclerotic disease in iliac arteries is experienced by 15% of all men and 5% of all women. TAC II recommends angioplasty for type-A, -B, and -C lesions. As regards stent type, self-expanding stent (SE, more elasticity) vs. balloon-expandable stent (SB, more radial strength), Reekers indicates superior target lesion revascularization (TLR) with SE. However, there

Novedades en las guías de prevención primaria de la AHA/ACC

CANTOS: Anti-inflammatory Drug Canakinumab Seems to Reduce CV Events

This human monoclonal antibody that specifically targets inflammatory cells seems to reduce cardiovascular events when associated with optimal medical therapy, according to a new study presented at the European Society of Cardiology Congress and published simultaneously in the New England Journal of Medicine. The CANTOS trial enrolled 10,061 patients with a previous infarction and high C-reactive

Sorpresivo hallazgo en diabetes y permeabilidad de los bypass

Striking Finding on Diabetes and Bypass Graft Patency

The higher rate of restenosis in the diabetic population is historic and has been reproduced in all studies and with all kinds of stents, but it was only after the FREEDOM trial when we found out about the higher infarction rate with PCI compared to surgery. This is why 50% of patients undergoing CABG are diabetic. Apart from the above

La revascularización incompleta se asocia a mortalidad en el TAVI

Incomplete Revascularization Is Associated with Mortality in TAVR

Courtesy of Dr. Carlos Fava. TAVR has proven to be beneficial for inoperable and high-risk patients, as well as for intermediate-risk patients. However, while many comorbidities have been analyzed, the presence, severity, and impact of coronary disease has not been well studied yet. This study analyzed 1270 patients who underwent TAVR. They presented >50% lesions in a major epicardial

Stent directo vs angioplastia convencional y sus interacciones con la trombo-aspiración

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the list of endovascular treatment options for coronary disease. The ABSORB III trial showed the non-inferiority of this stent type to everolimus-eluting metallic stents as regards target-lesion revascularization (TLR) at one year. However, reports have suggested a higher

FUTURE: aumento de la mortalidad en la rama FFR

FUTURE: Mortality Increase in the FFR Arm, Real or Casual?

The FUTURE study, testing the utility of functional revascularization by measuring the fractional flow reserve (FFR), was halted early by its safety committee due to an increased mortality rate at 1 year among patients guided by FFR.   In this unexpected unprecedented outcome, 17 patients in the FFR-guided group died at a year of follow-up, compared with 7 patients

Beta-Blockers for Revascularized Patients: To Prescribe or Not?

This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful coronary angioplasty in patients with stable chronic angina WITHOUT prior history of acute myocardial infarction or heart failure.   The benefit of beta-blockers in patients with acute myocardial infarction or systolic heart failure is well documented. However, their

celulas madre angina refractaria

Stem Cells: A New Alternative for Refractory Angina?

Courtesy of Dr. Agustín Vecchia.   Recent investigations and certain randomized trials suggest that the administration of CD34+ stem cells to patients with refractory angina improves exercise tolerance and decreases angina frequency.   The following is a phase 3, randomized, double-blind multicenter trial comparing three groups of patients: active treatment through intramyocardial administration of CD34+ stem cells (autologous, purified), standard of care

Top